Compare McKesson Corporation (MCK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Recursion Pharmaceuticals Inc — how do they compare? McKesson Corporation trades at $840 (market cap $98.51B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.56B). The key difference: McKesson Corporation is far larger — about 63.1× Recursion Pharmaceuticals Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MCK | RXRX | |
|---|---|---|
Market Cap | $98.51B | $1.56B |
Sector | Health | Health |
52-Week High | $995.69 | $6.79 |
52-Week Low | $659.01 | $2.84 |
Enterprise Value | $103.15B | $978.40M |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $841.39, showing minimal daily movement with a 0.01% gain. The stock maintains strong technical momentum with bullish moving averages and trades above key support levels. Fundamentally, the company demonstrates robust revenue growth reaching $359.05 billion in 2025, though profit margins remain thin at 1.18%. Recent quarterly earnings have consistently exceeded expectations, with Q1 2026 EPS of $11.69 beating estimates by $0.13.
MCK presents a compelling investment case with 80% analyst buy ratings and a $932.83 consensus price target suggesting 11% upside potential. The company benefits from strong cash flow generation ($6.09B operating cash flow) and improving debt metrics. Key risks include competitive pressures in healthcare distribution and execution challenges in maintaining growth momentum amid economic uncertainties.
Recursion Pharmaceuticals (RXRX) trades at $2.945, down 2.48% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The clinical-stage biotech company reported Q1 2026 EPS of -$0.22, beating expectations by $0.08, but maintains negative profitability metrics with a -851.51% net income margin. Analyst sentiment is mixed with 40% buy ratings and a $7.83 consensus price target representing 166% upside potential from current levels.
While RXRX shows promising AI-driven drug discovery technology and consistent earnings beats, the stock faces significant fundamental challenges including substantial cash burn (-$371.81M operating cash flow in 2025) and negative profitability. The bearish technical picture and high valuation (P/S of 21.43) create near-term headwinds, though long-term potential exists if the company can successfully commercialize its pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
